2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1305

Risk of Progression of Interstitial Lung Disease with Autoimmune Features to a Systemic Autoimmune Rheumatic Disease

Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis

9:00AM-11:00AM: Abstract Number: 1127

Risk of Stroke Among Patients with Gout in Taiwan: A Nationwide Population Study

Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

9:00AM-11:00AM: Abstract Number: 1116

Risk of Systemic Sclerosis According to Charge of the HLA-DRβ1 Third Hypervariable Region

Systemic Sclerosis and Related Disorders – Basic Science Poster II

9:00AM-11:00AM: Abstract Number: 1416

Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous

9:00AM-11:00AM: Abstract Number: 1304

Rituximab in Connective Tissue Disease – Associated Interstitial Lung Disease

Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis

9:00AM-11:00AM: Abstract Number: 1233

Rituximab Safety in Patients with Rheumatoid Arthritis. an Eleven-Year Follow-up Observational Study

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 1303

Rituximab Versus Mycophenolate Mofetil in Interstitial Lung Disease Secondary to Connective Tissue Disease

Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis

9:00AM-11:00AM: Abstract Number: 1571

RNA Sequencing Detection of Gene Dysregulation in Epithelial Cells Sorted from Salivary Gland Tissue Reveals Interesting Pathways Involved in Primary Sjögren’s Syndrome Pathophysiology

Sjögren's Syndrome – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 1349

Rnaseq of Peripheral Blood Mononuclear Cells from Juvenile Dermatomyositis, Necrotizing Myopathy and Controls Are an Aid in Diagnosis

Muscle Biology, Myositis and Myopathies Poster II: Basic and Translational Science

9:00AM-11:00AM: Abstract Number: 1063

Role of Mitochondrial-Bound HK2 in Rheumatoid Arthritis Fibroblast-like Synoviocytes

Rheumatoid Arthritis – Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1686

Rule-Based Algorithm Using Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria to Identify Patients with Systemic Lupus Erythematosus (SLE) from Electronic Health Record (EHR) Data

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1470

Russell Bodies and Serological Status in Rheumatoid Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1715

Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects

Systemic Sclerosis and Related Disorders – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1539

Safety of Methotrexate and Leflunomide Combination Therapy in the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

9:00AM-11:00AM: Abstract Number: 1413

Safety of Tocilizumab in Patients Aged <2 Years with Active Systemic Juvenile Idiopathic Arthritis Treated for One Year

Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].